The objective of this study was to assess the impact of manufacturing-scale, freeze-thaw conditions on aggregation and subvisible particle formation of a monoclonal antibody solution (mAb-A; IgG1) using a small-scale model.
W. Aaron Pruett
Advertisement
W. Aaron Pruett is drug product process engineer, Novavax.
Articles by W. Aaron Pruett
Advertisement
Latest Updated Articles
Impact of Manufacturing-Scale Freeze-Thaw Conditions on a mAb SolutionPublished: February 1st 2017 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Welcome to CPHI Frankfurt 2025
2
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
3
Novartis–Avidity Biosciences Deal Highlights Next-Gen RNA Manufacturing Potential
4
Regulatory Challenges for Global Manufacturing of Vaccines
5
